KOC
TXG icon

Koss-Olinger Consulting’s 10x Genomics TXG Stock Holding History

Koss-Olinger Consulting’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,763
Closed -$216K – 235
2022
Q2 		$216K Hold
4,763
– – 0.04% 157
2022
Q1 		$362K Hold
4,763
– – 0.06% 134
2021
Q4 		$709K Sell
4,763
-300
-6% -$46K 0.11% 75
2021
Q3 		$737K Sell
5,063
-1,500
-23% -$258K 0.12% 84
2021
Q2 		$1.28M Buy
+6,563
New +$1.19M 0.19% 61

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Koss-Olinger Consulting's TXG Position: Q3 2022 in Review

Koss-Olinger Consulting sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 4,763 shares — an estimated $216K sold.

Koss-Olinger Consulting first reported a position in TXG in Q2 2021 and held it in 5 quarters. The position peaked at $1.28M in Q2 2021. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

  • Koss-Olinger Consulting reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
  • Koss-Olinger Consulting sold 4,763 10x Genomics shares in Q3 2022, an estimated $216K.
  • Koss-Olinger Consulting first reported a position in 10x Genomics in Q2 2021 and held it in 5 quarters.
  • Koss-Olinger Consulting's 10x Genomics position peaked at $1.28M in Q2 2021.
  • 233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Koss-Olinger Consulting's 13F filing for Q3 2022, filed 14 Nov 2022.